Drug
Elvitegravir clinical trials
Also written GS-9137.
Counted the way a researcher would: Elvitegravir with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
Keep track of what changes. Save the elvitegravir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2015 (7)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 6 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 5
Gilead Sciences (20) · Janssen Sciences Ireland UC (1) · Technical University of Munich (1) · Fundacion Clinic per a la Recerca Biomédica (1) · St Stephens Aids Trust (1) · Juan A. Arnaiz (1) · Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic (1)
Often tested with
Tested in the same studies.
Cobicistat (22) · Emtricitabine (21) · Tenofovir alafenamide (19) · Darunavir (3) · Bictegravir (2) · Atazanavir (2) · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Fumarate (2) · Emtricitabine tenofovir alafenamide (2)
Related medicines
As reviewed, each with the page that says it.
- One of Integrase Inhibitors source
Studies
Open first, then newest update. How each study uses elvitegravir is read from its arms, and is right about nine times in ten.
Testing it · 26
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingPhase 4Gilead SciencesNCT06337032Written as E/C/F/TAF
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV NaiveWithdrawnPhase 4Juan A. ArnaizNCT02470650Written as elvitegravir/cobicistat/emtricitabine/tenofovir
- Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsCompletedPhase 3Gilead SciencesNCT01815736Written as E/C/F/TAF
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic HemodialysisCompletedPhase 3Gilead SciencesNCT02600819Written as E/C/F/TAF
- Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184ICompletedPhase 3Gilead SciencesNCT02616029Written as E/C/F/TAF
- Same-Day Treatment With Genvoya vs. EFV/TDF/3TCWithdrawnNot applicableHaitian Group for the Study of Kaposi's Sarcoma and OpportunisticNCT03405194Written as Elvitegravir, Cobicistat, TAF, FTC
- Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected WomenCompletedPhase 3Gilead SciencesNCT02652624Written as E/C/F/TAF
- Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 YearsCompletedPhase 3Gilead SciencesNCT02616783Written as E/C/F/TAF
- Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal ImpairmentCompletedPhase 3Gilead SciencesNCT01818596Written as E/C/F/TAF
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedPhase 3Gilead SciencesNCT01797445Written as E/C/F/TAF
- Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected AdolescentsCompletedPhase 2/3Gilead SciencesNCT02276612Written as E/C/F/TAF
- Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedPhase 2Gilead SciencesNCT01497899Written as E/C/F/TAF
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedPhase 3Gilead SciencesNCT01780506Written as E/C/F/TAF
- Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected AdultsCompletedPhase 3Gilead SciencesNCT02071082Written as E/C/F/TAF
- Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced AdultsCompletedPhase 3Gilead SciencesNCT01967940Written as E/C/F/TAF
- Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive AdultsCompletedPhase 3Gilead SciencesNCT01968551Written as E/C/F/TAF
- Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV TreatmentCompletedPhase 3Gilead SciencesNCT02707601Written as E/C/F/TAF
- Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected AdultsCompletedPhase 3Gilead SciencesNCT02605954Written as E/C/F/TAF
- Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric ParticipantsTerminatedPhase 2/3Gilead SciencesNCT01923311Written as EVG
- Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose CombinationCompletedPhase 1Janssen Sciences Ireland UCNCT02475135Written as Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
See all 26 studies that test elvitegravir →
Given in every arm · 2 — elvitegravir is usual care beside what is tested
- Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed ChildrenCompletedPhase 2/3Gilead SciencesNCT01854775Written as E/C/F/TAF
- Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive WomenCompletedPhase 3Gilead SciencesNCT01705574Written as E/C/F/TAF
Codes
What other systems call elvitegravir · ClinicalTrials.gg INT004902
- MeSH (NLM) C509700elvitegravirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 4GDQ854U53ELVITEGRAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1306286Confirmed FDA, Wikidata
- Wikidata Q2740966elvitegravirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76493ElvitegravirOne source FDA
- DrugBank DB09101One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C509700 | elvitegravir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 4GDQ854U53 | ELVITEGRAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1306286 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2740966 | elvitegravir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76493 | Elvitegravir | One source FDA |
| DrugBank | DB09101 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.